A Real-world HCM-cohort Trial

Inclusion criteria

• Meet the clinical diagnostic criteria for HCM*;
• Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form, have good compliance, and are willing to undergo clinical follow-up.

• Clinical diagnosis of HCM is defined as left ventricular wall thickness ≥15mm at any position during diastole by.echocardiography or CMR (≥13mm if there is a family history of HCM or positive cardiac genetic testing), and other secondary factors (such as severe hepertension, aortic stenosis) causing myocardial hypertrophy are excluded.

Exclusion criteria

• Metabolic syndrome or hypertrophic cardiomyopathy-like syndromes associated with left ventricular hypertrophy, such as amyloid cardiomyopathy, sarcoidosis, Fabry disease, Danon disease or Noonan syndrome;
• Severe systemic hypertension and/or severe aortic stenosis (<1cm²);
• Comorbid malignant tumors;
• Comorbid with other end-stage diseases with an expected lifespan of less than 3 years;
• Comorbid with mental disorders;
• Currently participating in other clinical trials and not reaching the primary endpoint.